The New Challenge of Curing AML: Analysis of Mechanisms of Resistance of Target Drugs and Future Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 79
Special Issue Editor
Interests: acute myeloid leukemia; hemopoietic stem cell transplant; target therapy; mechanisms of resistance; minimal residual disease
Special Issue Information
Dear Colleagues,
The advent of new target drugs for use in treatment has improved the prognosis of AML without changing the indications for allogeneic transplantation. Only 30% of patients with adverse- and intermediate-risk AML survive in the long term. On this basis, understanding the mechanisms behind resistance is critical to treating AML. Identifying molecular mutations that emerge after treatment with target drugs can help to select new targets and their inhibitors. LSCs still represent the major unmet medical need in resistant and refractory disease. Analysis of the metabolism of LSCs and their resistance to target drugs also represents a potential attempt to identify targets for the eradication of minimal residual disease. Inhibitors of FLT3, IDH1-2, and BCL-2, as well as immunotherapies such as monoclonal antibodies, CART, and anti-PD1/PD-L1, should be analyzed in terms of escape mechanisms and future prospects.
We are pleased to invite authors in this field to write reviews discussing the mechanisms of resistance of new target drugs in AML. We will also accept original research articles analyzing the in vivo and in vitro resistance mechanisms of target drugs or escape mechanisms of LSCs and stroma, as well as articles reviewing currently available immunotherapies and immunological escape mechanisms. Discussions of target drugs, pharmacological characteristics and drug interactions with dosage adjustments are also welcome. Finally, there is a need to discuss the prospects of new drugs, currently under investigation, that can be used to overcome resistance.
I look forward to receiving your contributions.
Dr. Debora Capelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- AML
- FLT3 inhibitors
- BCL2 inhibitor
- MCL1
- IDH1-2 inhibitors
- venetoclax
- CAR-T
- anti-CD123 monoclonal antibodies
- anti-CD33 monoclonal antibodies
- anti-PD-1 and -PD-L1
